

<https://doi.org/10.1038/s44325-024-00011-z>

Risk factors for long-term cardiovascular post-acute sequelae of COVID-19 infection: A nested case-control study in Hong Kong

Check for updates

Qiuyan Yu^{1,2}, Min Fan¹, Celia Jiaxi Lin³, David Tak Wai Lui⁴, Kathryn Choon Beng Tan⁴, Kai Hang Yiu⁴, Ralph Kwame Akyea⁵, Nadeem Qureshi⁵, Francisco Tsz Tsun Lai^{1,2}, Eric Yuk Fai Wan^{1,2,6}, Xue Li^{1,2,4}, Esther Wai Yin Chan^{1,2,7,8}, Ian Chi Kei Wong^{1,2,7,9,10} & Celine Sze Ling Chui^{2,3,11} ✉

People with COVID-19 can experience post-acute sequelae of SARS-CoV-2 (PASC). Studies on risk factors of PASC outcomes are ongoing, especially for endocrine system-related diseases that may impact the cardiovascular system. Cardiac-related PASC is one of the burdens after COVID-19 infection. This study aimed to examine the risk factors of cardiac-related PASC. In this nested case-control study, we obtained electronic health records (EHRs) database from the Hong Kong Hospital Authority. We defined cases as patients with at least one cardiac-related PASC and controls as patients without any cardiac-related PASC. We applied the incidence density sampling and matched controls to cases on age and sex at a 1:10 ratio. Multivariable conditional logistic regression was used to determine the associations between risk factors and cardiac-related PASC. A total of 455 individuals with cardiac-related PASC and matched 3,423 controls were obtained in the underlying cohort. COVID-19-associated hospitalisation (aOR: 1.41, 95% CI: 1.03–1.93) and peripheral vascular disease (aOR: 2.98, 95% CI: 1.31–6.79) were associated with an increased likelihood of cardiac-related PASC. Higher doses of the COVID-19 vaccine (2 doses: 0.68 [0.52–0.89]; ≥ 3 doses: 0.56 [0.40–0.78]) and more frequent healthcare utilization visits (aOR: 0.95, 95% CI: 0.92–0.97) were associated with a lower likelihood of cardiac-related PASC. This is the first study to examine risk factors of cardiac-related PASC among the Chinese population. We identified peripheral vascular disease and COVID-19-associated hospitalisation as the risk factors for cardiac-related PASC. COVID-19 vaccination was protective against cardiac-related PASC, which should be prioritized for high-risk patients.

SARS-CoV-2 infection (coronavirus disease 2019, COVID-19) has been reported to be associated with an increased risk of morbidity and mortality worldwide in the acute stage of infection within the first two weeks^{1–3}. The Literature has demonstrated that people who have COVID-19 infection can experience some potential long-term symptoms and conditions following the acute stage, namely post-acute sequelae of SARS-CoV-2 (PASC)^{4,5}. PASC can be defined as the persistence of symptoms or sequelae beyond three weeks of COVID-19 infection onset⁶. Increased risk of PASC involving multiple-organ systems, cardiovascular and all-cause mortality among patients with COVID-19 infection has been reported in recent studies^{7,8}. Research studies have identified some risk factors associated with PASC outcomes, including

the severity of symptoms during acute COVID-19 infection, increasing age, female sex, and pre-existing comorbidities^{9,10}. Yet, studies are still ongoing regarding the risk factors of PASC, especially for endocrine system-related diseases which may have a significant impact on the cardiovascular system¹¹. Various cardiovascular disease (CVD) including stroke, atrial fibrillation, and heart failure was reported as potential PASC within 12 months after COVID-19 infection^{12,13}. The cardiac-related PASC was also reported among patients with COVID-19 infections but without hospitalisation during the acute stage^{12,14}. Survivors of COVID-19 commonly experience cardiac-related PASC such as chest pain, heart palpitations, tachycardia, and fainting, with significant symptoms lasting for months after infection^{15–17}.

A full list of affiliations appears at the end of the paper. ✉ e-mail: cschui@hku.hk

Alpo Vuorio et al. have discussed the impact of the acute phase of COVID-19 on endothelial function leading to concern towards chronic metabolic conditions, especially in patients with familial hypercholesterolemia (FH) known as a metabolic inherited disease that will adversely affect endothelial function¹⁸. A follow-up study has highlighted the concerns related to the long-term effects of COVID-19 and the increased risk of complications and potentially poor outcomes among patients with FH¹⁹. A recent study from the US database also shows that COVID-19 increases the risk of myocardial infarction (MI) in FH patients with or without diagnosed atherosclerotic cardiovascular disease²⁰. It was reported that FH was associated with an increased risk of long-term sustained cardiovascular risk following COVID-19²¹.

Considering the long-term effect following COVID-19 for patients with FH and the risk of FH itself developing CVD in an early stage, it is important to examine FH as a risk factor for cardiac-related PASC among patients with COVID-19 infection. Identifying the potential risk factors integrating FH status for cardiac-related PASC outcomes can provide information to help monitor and multidisciplinary care for COVID-19 survivors. In addition, lack of evidence presents the risk factors including the Sinovac-CoronaVac vaccination for cardiac-related PASC in the Chinese population. Given that risk factor profiles may vary across ethnicities, and Sinovac-CoronaVac was uniquely developed and used in China, it is necessary to include the vaccination to investigate the effect on cardiac-related PASC in the Chinese population. This study aims to examine the potential risk factors related to cardiac-related PASC among patients infected with COVID-19 infection.

Results

We obtained 237,745 patients with COVID-19 infection who have at least one lipid cholesterol record (LDL-C or TC) as the underlying cohort, of whom 103,515 (43.5%) were men, with a mean age (\pm SD) of 58.8 (14.3) years. We identified 455 cases in the underlying cohort and matched 3423 controls at a 1:10 ratio. Figure 1 shows the underlying cohort selection process.

The baseline characteristics of the cases and controls are summarised in Table 1. The SMD of most baseline characteristics was ≤ 0.1 indicating that the variables were well-balanced between the cases and controls, except the age, Charlson Comorbidity Index, the doses of COVID-19 vaccines received, the antiviral prescription of COVID-19, the COVID-19 associated hospitalisation and healthcare utilisation, as well as the disease history such as peripheral vascular disease and chronic kidney disease. The most common comorbidities were hypertension (46.3%) and type 2 diabetes (22.2%). Cardiac-related PASC cases were older (mean age 70.4 vs. 68.7 years) and had a higher Charlson Comorbidity Index (0.6 vs. 0.5). More cardiac-related PASC cases did not receive COVID-19 vaccines (24.4% vs. 15.1%) while controls received more than 1 or 2 doses of COVID-19 vaccines (1 dose: 9.7% vs. 12.2%; 2 doses: 30.1% vs. 37.5%). Cardiac-related PASC cases were more prescribed with antiviral drugs for COVID-19 than controls (17.6% vs. 12.2%). In addition, more cardiac-related PASC cases have COVID-19-associated hospitalisation (16.9% vs. 8.3%) but less healthcare utilisation (mean visits 3.5 vs. 4.6).

For the potential risk factors, we found that patients with COVID-19 associated hospitalisation (aOR: 1.41, 95% CI: 1.03–1.93) and peripheral vascular disease (aOR: 2.98, 95% CI: 1.31–6.79) had a greater likelihood of having cardiac-related PASC. Patients who received more doses of the COVID-19 vaccine were found to have a lower likelihood of having cardiac-related PASC (2 doses: 0.68 [0.52–0.89]; ≥ 3 doses: 0.56 [0.40–0.78]). Patients with more frequent healthcare utilisation within 2 years also had a lower risk of cardiac-related PASC (aOR: 0.95, 95% CI: 0.92–0.97). Table 2 shows the results of univariate and multivariable regression analyses with all the potential risk factors.

Subgroup and sensitivity analysis

Subgroup analyses conducted reported results in Supplementary Tables S3–S6. Patients with peripheral vascular disease have a greater likelihood of having cardiac-related PASC in the group aged 40–65 (aOR: 3.82, 95% CI: 1.02–14.31), men (aOR: 3.00, 95% CI: 1.20–7.50), Charlson Comorbidity

Fig. 1 | Flowchart of cohort selection. PCR polymerase chain reaction, RAT rapid antigen test, PASC post-acute sequelae of SARS-CoV-2, LDL-C low-density lipoprotein-cholesterol, TC total cholesterol.




Table 1 | Baseline characteristics of the cases and controls

Baseline characteristic	Cases (N = 455)		Controls (N = 3423)		SMD ^b
	N/Mean	%/SD	N/Mean	%/SD	
Demographics					
Age, years ^a	70.4	13.4	68.7	12.0	0.134
Sex, male	273	60.0	2079	60.7	0.015
Charlson Comorbidity Index ^a	0.6	1.3	0.5	1.1	0.105
Pre-existing morbidities					
Peripheral vascular disease	9	2.0	19	0.6	0.128
Respiratory disease	21	4.6	130	3.8	0.041
Chronic obstructive pulmonary disease	21	4.6	130	3.8	0.041
Paralysis	0	0.0	0	0.0	<0.001
Type 2 diabetes	108	23.7	754	22.0	0.041
Chronic kidney disease	21	4.6	89	2.6	0.108
Mild liver disease	2	0.4	21	0.6	0.024
Moderate-severe liver disease	0	0.0	10	0.3	0.077
Ulcers	7	1.5	87	2.5	0.071
Rheumatoid arthritis and other Inflammatory polyarthropathies	5	1.1	32	0.9	0.016
Malignancy	29	6.4	195	5.7	0.028
Metastatic solid tumour	6	1.3	29	0.8	0.046
Hypertension	194	42.6	1600	46.7	0.083
Mental disorders	47	10.3	293	8.6	0.061
FH screened by FAMCAT ^a	0.0	0.0	0.0	0.0	0.020
Doses of COVID-19 vaccines received					0.258
0	111	24.4	518	15.1	
1	44	9.7	416	12.2	
2	137	30.1	1284	37.5	
3 or above	163	35.8	1205	35.2	
Antiviral Prescription for COVID-19 ^c	80	17.6	417	12.2	0.152
COVID-19 associated hospitalisation	77	16.9	283	8.3	0.263
Healthcare utilisation within 2 years ^a	3.5	4.3	4.6	4.8	0.238

SMD Standardized mean difference.

^aAge, Charlson Comorbidity Index, FH screened by FAMCAT, and healthcare utilisation are presented in mean ± Standard Deviation (SD).^bSMD ≤ 0.1 is considered a good balance between cases and controls.^cAntiviral prescription for COVID-19 was defined as prescribed Molnupiravir, Paxlovid, or Remdesivir within five days after being infected with COVID-19.

Index below 4 (aOR: 2.64, 95% CI: 1.12–6.19), and received vaccine 3 doses or above (aOR: 9.79, 95% CI: 2.10–45.56). COVID-19-associated hospitalisation only presented as one of the risk factors in females (aOR: 1.73, 95% CI: 1.07–2.80) and the group of patients who received 2 doses of vaccine (aOR: 2.92, 95% CI: 1.23–6.91).

Sensitivity analyses reported relatively consistent results in the aforementioned risk factors (Supplementary Tables S7–S10). In the first sensitivity analysis with PCR-tested positive patients only, COVID-19-associated hospitalisation and peripheral vascular disease became an insignificant risk factor, while type 2 diabetes was significantly associated with the high risk of cardiac-related PASC (aOR: 1.40, 95%CI: 1.01–1.94). When we extend the case identification period to 22–180 days, COVID-19-associated hospitalisation also became an insignificant risk factor on the outcome, while peripheral vascular disease presented a much higher likelihood of having cardiac-related PASC (aOR: 4.50, 95% CI: 1.81–11.16). When we matched the cases and controls without limit and used the threshold of 0.0047 for FAMCAT to dichotomise FH status, the pattern of risk factors was similar to the primary analysis.

Additional analysis

We found all of the COVID-19 vaccine subtypes were significantly associated with a lower likelihood of having cardiac-related PASC, except one

dose of BNT162b2 and two doses BNT162b2 followed by one dose Sinovac-CoronaVac (Supplementary Table S11). We did not find a significant association between antiviral treatments and cardiac-related PASC (Supplementary Table S12).

Post hoc analysis

We did not find any of the ICU admissions, COVID-19-associated pneumonia, or positivity of cardiac injury markers are significantly associated with cardiac-related PASC. The estimations of other risk factors are consistent with the main analysis (Supplementary Table S13).

Discussion

This is the first population-based study examining cardiac-related PASC risk factors in the Chinese population. The study considered FH as one of the risk factors and estimated the effect of both Sinovac-CoronaVac and BNT162b2 COVID-19 vaccine in developing cardiac-related PASC among patients with COVID-19 infection. We found that COVID-19-associated hospitalisation and peripheral vascular disease were associated with an increased likelihood of cardiac-related PASC diagnosis in the database. COVID-19 vaccination and healthcare utilisation within 2 years were associated with a lower likelihood of cardiac-related PASC diagnosis. Our findings were fairly consistent in the sensitivity analyses using a

Table 2 | Univariate regression and multivariable regression analysis results

Potential Risk Factors	N ^a	Univariate regression analysis		Multivariable regression analysis	
		OR (95% CI)	P-value	aOR (95% CI)	P-value
FH screened by FAMCAT	–	0.142 (0 - Inf)	0.878	0.50 (0.00 - Inf)	0.951
Vaccine status					
0–1 dose	1089	Ref		ref	
2 doses	1421	0.60 (0.47–0.79)	<0.001**	0.68 (0.52–0.89)	0.004*
≥3 doses	1368	0.49 (0.35–0.68)	<0.001***	0.56 (0.40–0.78)	<0.001**
Healthcare utilisation within 2 years	–	0.94 (0.92–0.97)	<0.001***	0.95 (0.92–0.97)	<0.001**
COVID-19 associated hospitalisation	360	1.66 (1.22–2.26)	0.001*	1.41 (1.03–1.93)	0.035*
Charlson Comorbidity Index	–	1.10 (1.02–1.19)	0.018*	1.04 (0.95–1.14)	0.365
Peripheral vascular disease	28	3.62 (1.62–8.10)	0.002*	2.98 (1.31–6.79)	0.009*
Hypertension	1794	0.83 (0.67–1.01)	0.062	1.01 (0.80–1.29)	0.913
Type 2 diabetes	862	1.13 (0.89–1.43)	0.323	1.16 (0.89–1.51)	0.275
Mental disorders	340	1.20 (0.86–1.68)	0.291	1.09 (0.77–1.54)	0.628

OR odds ratio, aOR adjusted odds ratio, 95% CI: 95% confidence interval.

*** P-value < 0.0001, ** P-value < 0.001, * P-value < 0.05.

^aNumber of observations: Continuous variables are not presenting an observation number.

variety of approaches to select cases, controls, match, and screen FH with a threshold.

Consistent with previous findings²², our study found that patients with COVID-19-associated hospitalization have a high risk of cardiac-related PASC. Currently, there is a lack of studies that specifically focus on cardiac-related PASC and investigating the Sinovac-CoronaVac and BNT162b2 COVID-19 vaccine safety and effectiveness related to thromboembolism and carditis outcomes. Our study indicates that having COVID-19 vaccination with increased doses, regardless of the subtypes, is protective against cardiac-related PASC, supporting the importance of being vaccinated and the benefit of vaccination outweighs risks^{23,24}. In addition, the COVID-19 vaccine was found to be effective in reducing COVID-19-associated hospitalisation in our team research^{25,26}, taking vaccination should be highly prioritised for those high-risk patients to protect against developing cardiac-related PASC. We further explored the impact of the severity associated with COVID-19 infection on cardiac-related PASC outcomes in the post hoc analysis. The findings showed that the added estimated factors are not significantly associated with cardiac-related PASC, with other factors remaining consistent. We believe this may indicate that COVID-19 hospitalisation is a strong indicator of severity for cardiac-related PASC.

Previous studies have shown that the presence of comorbidities is related to a significantly increased risk for general PASC development^{9,27}. Our study added to the literature by examining comorbidities, including peripheral vascular disease, hypertension, type 2 diabetes, mental disorders, and FH as the potentially cardiac-related PASC risk factors. As the common risk factors of CVD outcomes, we only found peripheral vascular disease was significantly associated with a higher likelihood of cardiac-related PASC in this study. In the context of exclusion criteria in this study, we have excluded individuals with serious CVD that occurred before infection (e.g., MI, stroke, CAD, etc.). It is important to note that even individuals with milder CVD-related conditions may be at an exacerbated condition triggered by COVID-19 with an increased risk of developing cardiac-related PASC. Therefore, this group of patients should be well-managed with prioritised for vaccination to provide better protection, which was found to have a protective effect in our study.

In the subgroup analysis, we observed similar patterns of risk factor distribution. We found peripheral vascular disease was significantly associated with a higher likelihood of cardiac-related PASC in the male group instead of the female group, which may be due to the sample size that the percentage of men is larger than women. When we look into the baseline characteristics, it is interesting that patients with cardiac-related PASC are

more likely to have antiviral prescriptions for COVID-19. This may indicate that patients who used antiviral drugs are likely to be sicker than those without antiviral drugs. In addition, patients with COVID-19 who are over 60 years old or have comorbidities like diabetes and CAD would be prescribed antiviral treatment. Since the prevalence of most comorbidities was higher among cardiac-related PASC cases than controls, this may also account for the higher usage of antiviral prescriptions. However, we did not find a significant association between antiviral drugs and cardiac-related PASC outcomes in the additional analysis.

Prior work has reported that pre-existing anxiety and depression are associated with an increased risk of PASC²⁸. However, our study did not find a significant association between pre-existing mental disorders and the development of cardiac-related PASC. Another study conducted by Hill¹⁰ found that a pre-existing diagnosis of depression was associated with a higher risk of subsequent PASC, however, prior diagnoses of other mental health diagnoses (e.g., psychosis) were associated with lower risk. Different types of mental disorders may play different roles with different mechanisms in developing PASC. To further understand mental disorders on cardiac-related PASC, we may need to separate them into specific conditions to investigate the effect further.

While Alpo Vuorio et al.²¹ reported that FH was associated with an increased risk of CVD after COVID-19, we did not find a significant association between FH and cardiac-related PASC. However, we believe this study demonstrated the application of FAMCAT in EHRs databases. Compared with the Dutch Lipid Clinic Network (DLCN), one of the internationally recommended clinical algorithms to detect FH²⁹, screening for FH with FAMCAT in EHR is more practicable, which requires automated correction of LDL-C level with concurrent lipid-lowering medication parameters³⁰. In contrast, DLCN is strongly determined by the LDL-C level without considering the effect of lipid-lowering medications. FAMCAT could enable passive surveillance to screen patients likely to have FH using EHRs.

In this nested case-control study, misclassification bias may be the common limitation. Within the case identification period, the controls in the nested cohort may have had any cardiac-related PASC outcome but have not yet been diagnosed in the database. It may lead to underestimation of certain conditions of cardiac-related PASC, including cardiomyopathy, atrial fibrillation, myocarditis, and pericarditis, which may not always present with obvious symptoms. To reduce the bias, we did a sensitivity analysis which prolonged the case identification period to allow more time for patients to get an accurate diagnosis, increasing the validity of case and

control identification. In addition, the database used in this study has been validated with a high coding accuracy, especially for cardiovascular outcomes. Similar limitations were also presented on the patient inclusion with COVID-19 infection. This study includes those patients with COVID-19 tested PCR or reported RAT positive in the HK population. Yet, there is still a large proportion of HK residents who get the infection but have not officially tested or reported positive recorded in the database. We cannot capture this part of patients, though, we believe there is enough sample size in the whole set, with over 90% of HK residents already getting infections. Another limitation is that we only limited the data to those who have lipid measures due to the calculation of FH likelihood using FAMCAT. Nevertheless, our study is the first that evaluated the risk factors of cardiac-related PASC among the Chinese population, incorporating the effect of Sinovac-CoronaVac vaccine and FH screened by FAMCAT, the primary sample size enabling us to identify some statistically meaningful risk factors. Lastly, even if we found an association between peripheral vascular disease and cardiac-related PASC, the number of patients with peripheral vascular disease is small due to the incident cases. In addition, as a common limitation of many EHRs, smoking data is unavailable in our database. Disease symptoms, lifestyle, and socioeconomic status data may not be fully captured in the database. We used COVID-19-associated hospitalisation as a proxy for those unmeasured factors and disease severity in the analysis. Further studies with available data are required to validate the study findings. While the study findings were robust for the Hong Kong population, their generalizability to other countries or regions may be limited. Further studies on other populations may be needed to confirm the robustness of the results.

In conclusion, this study is the first to examine risk factors of cardiac-related PASC among the Chinese population. We identified some important risk factors such as peripheral vascular disease and COVID-19-associated hospitalisation. COVID-19 vaccination was protective against cardiac-related PASC, which should be prioritised for high-risk patients.

Methods

Data sources

In this nested case-control study, we retrieved the electronic health records (EHRs) from the Hong Kong Hospital Authority. The Hospital Authority is a statutory body that manages all public hospitals and their ambulatory clinics in Hong Kong, China³¹. The service is available to all Hong Kong residents (>7.3 million) covering approximately 80% of all routine hospital admissions and all patients with COVID-19 in Hong Kong³¹. The database has been used in previous studies involving COVID-19 vaccine safety surveillance and effectiveness^{32–34}. The database has been validated with high coding accuracy and has been extensively used for conducting high-quality large population-based studies^{35–37}. We obtained the death records from the Hong Kong Deaths Registry to identify mortality in this study. Information on vaccination status was provided by the Department of Health, The Government of Hong Kong Special Administrative Region who is in charge of the only mass COVID-19 vaccination programme in Hong Kong during the study period.

Anonymised longitudinal clinical healthcare data since 2016 was obtained for all individuals from the database. Relevant data included baseline demographic (sex, age and Charlson Comorbidity Index), pre-existing comorbidities captured by clinical diagnosis codes using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) (Supplementary Table S1), COVID-19 vaccination status, antiviral prescription for COVID-19, COVID-19 associated hospitalisation and the healthcare utilisation at baseline.

Study design and patient population

This is a nested case-control study conducted on patients aged 18 years or above. The underlying cohort was identified as patients with laboratory-confirmed SARS-CoV-2 infection (confirmed by positive polymerase chain reaction [PCR] test in throat swab, nasopharyngeal aspirate, or deep throat sputum specimens) or patients detected with SARS-CoV-2 virus proteins (antigens) in respiratory specimens by rapid antigen test [RAT] between April 1, 2020 to October 31, 2022 from the database.

We considered the earliest date of the laboratory-confirmed or RAT-detected positive diagnosis of COVID-19 infection as the index date for each patient in the underlying cohort. Patients with a history of COVID-19 before the study start date were excluded to ensure the inclusion of patients with first COVID-19 during the study period. Individuals who had any COVID-19 vaccination 90 days after the first COVID-19 infection were excluded.

We defined the case and control identification period from 22 days to 90 days after patients' first COVID-19 infection (index date). The time between the index date and 21 days after was considered the acute phase. Individuals who had any cardiac-related PASC outcome before the index date and within the acute phase were also excluded. To ensure sufficient data to estimate FH likelihood, patients with at least one low-density lipoprotein-cholesterol (LDL-C) or total cholesterol (TC) record before the index date were included as the underlying cohort. Eligible individuals were followed up from the index date until each cardiac-related PASC outcome event occurred, death, or study end date (January 31, 2023), whichever occurred earlier.

Cases and controls

We identified the cases as patients who have at least one cardiac-related PASC in the identification period. The definition of cardiac-related PASC outcomes of this study was selected based on previous evidence on the risk of PASC, which includes incidences of stroke, MI, heart failure, atrial fibrillation, coronary artery disease (CAD), myocarditis and pericarditis, deep vein thrombosis, cardiomyopathy, and cardiovascular mortality^{12,38–41}. The cardiac-related PASC diagnoses were identified from the primary ranking in-patients' hospital records based on the ICD-9-CM code and death records were identified by the ICD-10-CM code in the database (Supplementary Table S2). We identified the controls as patients without any cardiac-related PASC in the identification period. The incidence density sampling was applied to select controls to obtain unbiased results⁴², in which the cases were allowed to be controls before their incident cardiac-related PASC. The pool of eligible controls includes all cohort members, with the exception of the index case itself. Up to ten controls were randomly selected without replacement from this pool of eligible controls to form the incidence density sampled risk set for the index case. Controls were matched to cases on attained age and sex. One control can be matched to more than one case.

Risk factors

We defined the potential exposures of risk factors as demographic (age, sex, and Charlson Comorbidity Index), vaccination status (0–1 doses, 2 doses, ≥3 doses), COVID-19 associated hospitalisation, outpatient healthcare utilisation visits, and a list of clinical diagnosis history (peripheral vascular disease, hypertension, type 2 diabetes, mental disorders, FH), reference from existing literature³⁸ and clinical expertise. As it is difficult to identify individuals with FH using the ICD-9-CM code in the EHR database, we used a case ascertainment tool named FAMCAT to measure the FH likelihood (Supplementary Information). FAMCAT is one of the validated tools in screening FH using the EHR database, enabling clinicians to estimate the probability of having FH⁴³. We used the information before the index date to identify patients' age, sex, Charlson Comorbidity Index, and FAMCAT probability. The vaccination status was defined as the doses of vaccination received at least 14 days before the index date. We defined COVID-19 associated hospitalisation as hospitalisation within 14 days after the first COVID-19 infection and healthcare utilisation as the count of outpatient visits within two years before the index date. The disease history was defined as either inpatient or outpatient diagnosis before the index date.

Statistical analysis

Descriptive statistics were used to report the characteristics of cases and controls at baseline. We estimated the standardised mean difference (SMD) between the cases and controls, with SMD ≤ 0.1 regarded as a sufficient balance between case and control groups. Univariate analysis was conducted

using conditional logistic regression to estimate the odds ratio (OR) and 95% confidence interval (95% CI) of each potential risk factor on the cardiac-related PASC outcomes among individuals with COVID-19 infection in the underlying cohort. We further conducted the multivariable conditional logistic regression for all the risk factors estimated in the univariate analysis presenting the adjusted odds ratio (aOR).

Subgroup and sensitivity analysis

We conducted the subgroup analyses with patients stratified by 1) age (<40, ≤65, >65); 2) sex; 3) Charlson Comorbidity Index (<4, ≥4); and 4) COVID-19 vaccination status prior to the index date (0–1 dose, 2 doses, ≥3 doses). We performed the sensitivity analyses by 1) defining the underlying cohort as patients with laboratory-confirmed SARS-CoV-2 infection (confirmed by PCR) only; 2) defining the cases as patients who have any cardiac-related PASC outcomes from 22 days to 180 days after the first tested positive date of COVID-19 infection; 3) matching cases and controls as much as possible without 1:10 limit; and 4) applying FAMCAT with a threshold of 0.0047 to dichotomise FH status.

Additional analysis

We performed an additional analysis by investigating the COVID-19 vaccination subtypes on the cardiac-related PASC. Vaccine subtypes were classified as one dose Sinovac-CoronaVac, one dose BNT162b2, two doses Sinovac-CoronaVac, two doses BNT162b2, three doses Sinovac-CoronaVac, three doses BNT162b2, two doses Sinovac-CoronaVac followed by one dose BNT162b2, two doses BNT162b2 followed by one dose Sinovac-CoronaVac. Patients who received four doses or above were categorised as three doses depending on their first three dose subtypes. We further conducted an additional analysis by including antiviral treatments as a potential risk factor for cardiac-related PASC. Antiviral treatments for COVID-19 were defined as prescribed Molnupiravir, Paxlovid, or Remdesivir within five days after being infected with COVID-19.

Post hoc analysis

To explore the impact of severity of COVID-19 on cardiac-related PASC, we conducted a post hoc analysis by including ICU admission, COVID-19-associated pneumonia, and positivity of cardiac injury markers in the model. We identified patients who presented any diagnosis with an ICD9 code of 519.8 as having COVID-19-associated pneumonia. We identified patients with detected positive myoglobin or higher test results of creatine kinase or troponin than their reference upper level recorded in the database as having a cardiac injury. All ICU admissions, COVID-19-associated pneumonia, and positivity of cardiac injury markers were identified within 14 days after the index date to reflect the severity of COVID-19 infection.

All statistical analyses were conducted using R version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria). All significance tests were two-tailed and 95% CI excluding 1.0 was taken to indicate statistical significance. Two investigators (QY and MF) conducted each statistical analysis independently for quality assurance.

Ethical approval for this study was granted by the Institutional Review Board of the University of HK/HA HK West Cluster (UW20-556 and UW21-149) and Department of Health, HK (LM21/2021 and LM175/2022) with an exemption for informed consent from participants as patients' confidentiality was maintained in this nested case-control study.

Data availability

The data underlying this article are available from the Hong Kong Hospital Authority and cannot be shared publicly as stipulated in the Institutional Review Board application protocol. Inquiries for data access can be made at enquiry@ha.org.hk.

Received: 11 March 2024; Accepted: 26 June 2024;
Published online: 02 August 2024

References

- Centre for Health Protection. Coronavirus Disease 2019 (COVID-19) [updated 31 July 2023. Available from: <https://www.chp.gov.hk/en/healthtopics/content/24/102466.html>.
- Datta, S. D., Talwar, A. & Lee, J. T. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. *JAMA* **324**, 2251–2252 (2020).
- Leung, T. Y. M. et al. Short- and potential long-term adverse health outcomes of COVID-19: a rapid review. *Emerg. Microbes Infect.* **9**, 2190–2199 (2020).
- Centers for Disease Control and Prevention. COVID-19. Long COVID or Post-COVID Conditions [updated July 20. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html>. (2023).
- Nalbandian, A. et al. Post-acute COVID-19 syndrome. *Nat. Med.* **27**, 601–615 (2021).
- Greenhalgh, T., Knight, M., A'Court, C., Buxton, M. & Husain, L. Management of post-acute covid-19 in primary care. *BMJ (Clin. Res. ed.)* **370**, m3026 (2020).
- Ayoubkhani, D. et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ*. **372**, n693 (2021).
- Visco, V. et al. Post-COVID-19 Syndrome: Involvement and Interactions between Respiratory, Cardiovascular and Nervous Systems. *J. Clin. Med.* **11**, 524 (2022).
- Jacobs, E. T. et al. Pre-existing conditions associated with post-acute sequelae of COVID-19. *J. Autoimmun.* **135**, 102991 (2023).
- Hill, E. L. et al. N3C Consortium; and the RECOVER Consortium. Risk factors associated with post-acute sequelae of SARS-CoV-2: an N3C and NIH RECOVER study. *BMC Public Health*. **23**, 2103 (2023).
- Binu, A. J. et al. The heart of the matter: cardiac manifestations of endocrine disease. *Indian J. Endocrinol. Metab.* **21**, 919–925 (2017).
- Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Long-term cardiovascular outcomes of COVID-19. *Nat. Med.* **28**, 583–590 (2022).
- Wan, E. Y. F. et al. Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank. *Cardiovasc. Res.* **119**, 1718–1727 (2023).
- Mantovani, A. et al. Long Covid: where we stand and challenges ahead. *Cell Death Differ.* **29**, 1891–1900 (2022).
- Ogungbe, O. et al. Cardiac postacute sequelae symptoms of SARS-CoV-2 in community-dwelling adults: cross-sectional study. *Open Heart*. **9**, e002084 (2022).
- Singh, T. K. et al. A post-pandemic Enigma: The cardiovascular impact of post-acute Sequelae of SARS-CoV-2. *Circ. Res.* **132**, 1358–1373 (2023).
- Groff, D. et al. Short-term and long-term rates of Postacute Sequelae of SARS-CoV-2 Infection: A systematic review. *JAMA Netw. Open* **4**, e2128568 (2021).
- Vuorio, A., Strandberg, T. E., Raal, F., Santos, R. D. & Kovanen, P. T. Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition. *Atherosclerosis* **43**, 3–6 (2021).
- Vuorio, A., Raal, F., Ijäs, P., Kaste, M. & Kovanen, P. T. Long-term cardiovascular and cerebrovascular challenges posed by COVID-19 in patients with familial Hypercholesterolemia. *Front. Pharmacol.* **13**, 890141 (2022).
- Myers, K. D. et al. COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD. *Am. J. Prev. Cardiol.* **7**, 100197 (2021).
- Vuorio, A., Watts, G. F. & Kovanen, P. T. Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk. *J. Intern. Med.* **287**, 746–747 (2020).
- Yoo, S. M. et al. Factors Associated with Post-Acute Sequelae of SARS-CoV-2 (PASC) After Diagnosis of Symptomatic COVID-19 in

- the Inpatient and Outpatient Setting in a Diverse Cohort. *J. Gen. Intern. Med.* **37**, 1988–1995 (2022).
23. Tran, V.T., Perrodeau, E., Saldanha, J., Pane, I. & Ravaud, P. Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort. *BMJ Med.* **2**, e000229 (2023).
 24. Notarte, K. I. et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. *EClinicalMed.* **53**, 101624 (2022).
 25. Wan, E. Y. et al. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA. 2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: a case control study. *J. Infect.* **85**, e140–e144 (2022).
 26. Huang, C. et al. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study. *Lancet Psychiatry* **10**, 403–413 (2023).
 27. Abdelwahab, N. et al. Predictors of Postacute Sequelae of COVID-19 development and rehabilitation: a retrospective study. *Arch. Phys. Med. Rehabil.* **103**, 2001–2008 (2022).
 28. Knight, D. R. T. et al. Perception, prevalence, and prediction of severe infection and post-acute Sequelae of COVID-19. *Am. J. Med. Sci.* **363**, 295–304 (2022).
 29. McGowan, M. P., Hosseini Dehkordi, S. H., Moriarty, P. M. & Duell, P. B. Diagnosis and treatment of heterozygous familial hypercholesterolemia. *J. Am. Heart Assoc.* **8**, e013225 (2019).
 30. Qureshi, N. et al. Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care. *Open Heart* **8**, e001752 (2021).
 31. Hospital Authority. Caring for our community's health [Available from: https://www.ha.org.hk/visitor/ha_visitor_index.asp?Parent_ID=10004&Content_ID=10008&Ver=HTML].
 32. Wan, E. Y. F. et al. Post-acute sequelae of COVID-19 in older persons: multi-organ complications and mortality. *J. Travel Med.* **30**, taad082 (2023).
 33. Yan, V. K. C. et al. Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case-control study. *Emerg. Microbes Infect.* **12**, 2209201 (2023).
 34. Wan, E. Y. et al. Association between BNT162b2 and CoronaVac vaccination and risk of CVD and mortality after COVID-19 infection: A population-based cohort study. *Cell Rep. Med.* **4**, 101195 (2023).
 35. Chan, E. W. et al. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: a population-wide cohort study. *Heart Rhythm* **13**, 1581–1588 (2016).
 36. Wong, A. Y. et al. Cardiovascular outcomes associated with use of clarithromycin: population based study. *bmj.* **352**, h6926 (2016).
 37. Chan, E. W. et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. *Gastroenterol.* **149**, 586–595 (2015).
 38. Daugherty, S. E. et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. *bmj.* **373**, n1098 (2021).
 39. Xie, Y. & Al-Aly, Z. Risks and burdens of incident diabetes in long COVID: a cohort study. *Lancet Diab. Endocrinol.* **10**, 311–321 (2022).
 40. Taquet, M. et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. *Lancet Psychiatry* **9**, 815–827 (2022).
 41. Xu, E., Xie, Y. & Al-Aly, Z. Long-term neurologic outcomes of COVID-19. *Nat. Med.* **28**, 2406–2415 (2022).
 42. Richardson, D.B. An incidence density sampling program for nested case-control analyses. *Occup. Environ. Med* **61**, e59 (2004).
 43. Akyea, R. K. et al. Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study. *BJGP open.* **4**, bjgpopen20X101114 (2020).

Acknowledgements

This work was supported by funding from the Collaborative Research Fund, University Grants Committee, the HKSAR Government (principal investigator, ICKW; ref. no. C7154-20GF); and a research grant from the Health Bureau, the HKSAR Government (principal investigator, ICKW; ref. no. COVID19F01). ICKW and FTTL are partially supported by the Laboratory of Data Discovery for Health (D24H) funded by the AIR@InnoHK administered by the Innovation and Technology Commission.

Author contributions

Q.Y., M.F., and C.S.L.C. contributed to the design and review of the study protocol. Q.Y. and M.F. retrieved and analysed the data independently. Q.Y. drafted the first draft of the manuscript. M.F., C.J.L., D.T.W.L., K.C.B.T., K.H.Y., R.K.A., N.Q., F.T.T.L., E.Y.F.W., X.L., E.W.Y.C., I.C.K.W. and C.S.L.C. provided critical input to the discussion and revision of the manuscript. C.S.L.C. supervised the project. All authors interpreted the data, reviewed and edited the manuscript, and approved the decision to submit for publication.

Competing interests

KCBT reports employment with the University of Hong Kong and speakers bureau for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, and Sanofi. EYFW has received research grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, and the Hong Kong Research Grants Council, and ADAMS Limited Hong Kong non-executive director outside the submitted work. FTTL has been supported by the RGC Postdoctoral Fellowship under the Hong Kong Research Grants Council and has received research grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, and ADAMS Limited Hong Kong non-executive director outside the submitted work. XL reported grants from Research Grant Council/Research Impact Fund, Research Grant Council/Early Career Scheme, Health and Medical Research Fund, Health and Medical Research Fund Fellowship Scheme, internal funding from University of Hong Kong Department of Medicine, startup funding from University of Hong Kong Li Ka Shing Faculty of Medicine, Jansson Educational Grant, Pfizer Investigator Initiated Research Grant; and personal fees from Pfizer, Merck Sharp & Dohme, and ADAMS Limited Hong Kong non-executive director; all outside the submitted work. EWYC reports honorarium from the Hospital Authority; and grants from the Research Grants Council (RGC, Hong Kong), Research Fund Secretariat of the Food and Health Bureau, National Natural Science Fund of China, Wellcome Trust, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, Takeda, and Narcotics Division of the Security Bureau of the Hong Kong Special Administrative Region, outside the submitted work. ICKW has received research grants from Amgen, Janssen, GSK, Novartis, Pfizer, Bayer and Bristol-Myers Squibb and Takeda, Institute for Health Research in England, European Commission, National Health and Medical Research Council in Australia, The European Union's Seventh Framework Programme for research, technological development, Research Grants Council Hong Kong and Health and Medical Research Fund Hong Kong; consulting fee from IQVIA and WHO; payment for expert testimony for Appeal Court in Hong Kong; serves on advisory committees for Member of Pharmacy and Poisons Board; Member of the Expert Committee on Clinical Events Assessment Following COVID-19 Immunization; Member of the Advisory Panel on COVID-19 Vaccines of the Hong Kong Government; is the non-executive director of Jacobson Medical in Hong Kong; is the Founder and Director of Therakind Limited (UK), ADAMS Limited (HK), Asia Medicine

Regulatory Affairs (AMERA) Services Limited and OCUS Innovation Limited (HK, Ireland and UK). CSLC has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, MSD, and Amgen, and personal fees from PrimeVigilance, and ADAMS Limited Hong Kong non-executive director outside the submitted work. All other authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s44325-024-00011-z>.

Correspondence and requests for materials should be addressed to Celine Sze Ling Chui.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024, corrected publication 2025

¹Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ²Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China. ³School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ⁴Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ⁵Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, United Kingdom. ⁶Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ⁷Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China. ⁸The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, China. ⁹Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom. ¹⁰Aston Pharmacy School, Aston University, Aston Street, Birmingham B4 7ET, United Kingdom. ¹¹School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ✉e-mail: cschui@hku.hk